Direct laboratory transfer programs supporting Thai FDA, ASEAN Cosmetic Directive, and PIC/S GMP analytical method qualification from our China research center.
How Thailand’s national “Medical Hub of Asia” initiative and revised Thai Herbal Pharmacopoeia (THP) create an urgent demand for advanced analytical method establishment.
The Thai Food and Drug Administration (TFDA) has systematically aligned domestic manufacturing requirements with international Pharmaceutical Inspection Co-operation Scheme (PIC/S) standards. For botanical drugs, nutraceutical formulations, and cosmeceuticals manufactured across Greater Bangkok (Pathum Thani, Samut Prakan, Samut Sakhon), rudimentary spectrophotometric assays no longer pass TFDA pre-market dossier scrutiny. Processors require validated chromatographic separation methods with high specificity and verified linear ranges.
Thailand’s Bio-Circular-Green (BCG) economic framework has catalyzed substantial foreign and domestic investment in herbal innovation hubs located along the Bangkok-Chonburi-Rayong logistics axis. As companies upscale tropical botanical extracts (such as Curcuma comosa, Kaempferia parviflora, Centella asiatica, and Andrographis paniculata) into standardized health supplements, the local analytical infrastructure experiences severe backlogs in chromatographic fingerprinting and reference standard synthesis.
The ASEAN Harmonized Regulatory Regime for Traditional Medicines and Health Supplements (TMHS) sets rigorous requirements on heavy metals, mycotoxins, microbiological limits, and assay validation across all Southeast Asian member states. Bangkok serves as the regional trading and manufacturing nerve center, meaning analytical dossiers established for Thai products must simultaneously comply with BP, USP, and Ph. Eur. criteria to ensure unfettered regional export.
Leveraging Changsha’s world-class natural medicine cluster, massive phytochemical libraries, and deep pharmacopoeial expertise to serve Bangkok’s production facilities.
One of the primary roadblocks faced by Bangkok QA/QC laboratories is obtaining reliable, high-purity chemical reference substances (CRS) for novel or multi-herb active ingredients. Operating from Changsha, Hunan—the historic capital of botanical extraction in China—our laboratory infrastructure routinely isolates, characterizes, and certifies reference markers via 1D/2D NMR, HR-ESI-MS, and elemental analysis. When establishing a custom HPLC method for an indigenous Thai or classic TCM herb, we do not rely on uncertain external standards; we synthesize and isolate authenticated reference markers in-house, ensuring 98%+ chromatographic purity.
Our analytical teams possess rigorous operational familiarity with the Chinese Pharmacopoeia (ChP), United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and the Thai Herbal Pharmacopoeia (THP). Method development packages engineered for the Bangkok market are designed from day one to withstand multi-agency audits. We systematically evaluate mobile phase gradients, column chemistries (core-shell, C18, HILIC, chiral), detector wavelengths, and mass fragmentation pathways to yield rugged methods capable of seamless transfer to client QA teams in Bangkok, Samut Prakan, or Chonburi.
| Evaluation Parameter | Local Greater Bangkok In-House Testing | Western Contract Research Organizations | Our China CRO/CDMO Facility (Yineng/MedGence) |
|---|---|---|---|
| Phytochemical Reference Availability | Constrained; heavy import duties and long lead times for secondary metabolites. | High catalog coverage for generic chemicals; scarce for specialized botanical fractions. | Direct In-House Isolation from hundreds of botanical species with verified NMR/MS certificates. |
| ICH Q2(R2) Validation Timelines | 12 to 24 weeks due to instrument queue backlogs in metropolitan universities. | 16 to 20 weeks with rigid project scopes and excessive administrative overhead. | 4 to 6 Weeks turnaround with dedicated multi-instrument suites (UPLC, HPLC-DAD, GC-MS/MS). |
| Complex Polyherbal Matrix Separation | Frequent baseline co-elution; difficulty isolating overlapping polyphenol peaks. | Limited experience with classical multi-herb formulation synergy and decoction matrixes. | 83+ Formulations Decoded; mastered fingerprint correlation methods and peak deconvolution. |
| Cost-Efficiency & Commercial Scale-Up | Moderate operational cost, but high capital lockup on experimental trial runs. | Extremely high analytical retainer fees and prohibitive method-transfer royalties. | Highly Cost-Effective with seamless pilot-plant and commercial CDMO OEM scale transfer. |
From target molecule screening to complete validation dossiers meeting ICH Q2(R1)/(R2), PIC/S, and TFDA regulatory requirements.
Crucial for botanical identity authentication and detection of deliberate or accidental adulteration. We establish automated, standardized HPTLC protocols utilizing CAMAG-grade digital imaging under 254 nm, 366 nm, and white light post-derivatization. These profiles satisfy TFDA identity testing for crude herbs and multi-component extracts entering Bangkok port customs.
Quantitation of active saponins, flavonoids, alkaloids, terpenes, and phenolic acids requires baseline resolution without peak tailing. We optimize mobile phase acid-modifiers, quaternary pump gradient profiles, and temperature curves to achieve peak purity indices exceeding 99.8%. Methods are rigorously validated across specificity, linearity (R² > 0.999), precision, and ruggedness.
For essential oils, volatile herbal aromatics, and Class 1, 2, and 3 extraction solvent residues (ethanol, methanol, ethyl acetate, acetone, hexane). We engineer static headspace and split/splitless capillary gas chromatography methods tailored to Bangkok industrial factories ensuring complete compliance with USP <467> and EP limits.
Demonstrating tangible value across nutraceutical, pharmaceutical, and functional cosmetic factories in Thailand’s central manufacturing zones.
Challenge: A leading softgel manufacturer located in Bang Phli, Samut Prakan, faced regulatory rejection from the Thai FDA due to lack of peak specificity and unacceptable variation (RSD > 6.8%) in their quantitative assay for a standardized lutein-curcumin combination capsule.
Solution: Yineng Biopharm / MedGence established a tandem HPLC-DAD method using a specialized core-shell C18 column with a gradient system that resolved baseline interference between carotenoids and curcumins. We isolated high-purity reference curcumoids, completed ICH-compliant precision and intermediate precision testing, and delivered a complete Analytical Validation Dossier within 28 business days.
Result: Rapid TFDA registration approval, saving approximately 9 months of product launch delay.
Challenge: A wellness and functional beverage enterprise operating in the Amata City industrial park required analytical verification to export Centella asiatica (Gotu Kola) Asiaticoside and Madecassoside extracts to Japan and the European Union under strict contaminant thresholds.
Solution: We developed a dual HPLC-ELSD (evaporative light scattering) method to accurately quantify triterpenoid glycosides devoid of chromophores, paired with a multi-residue GC-MS/MS assay for 120+ organochlorine and organophosphate pesticides matching European Pharmacopoeia 2.8.13 guidelines.
Result: Zero batch rejections at European and Japanese border inspections over 24 continuous shipment cycles.
Challenge: An established hospital preparation manufacturer in Khlong Luang, Pathum Thani, needed to transition an 8-herb traditional respiratory formula into a modern, standardized soluble granule while maintaining hospital registration compliance.
Solution: Utilizing our validated TCM formula modernisation framework (tested on 83 classical formulas), we established a comprehensive HPTLC and HPLC fingerprinting assay identifying four unique chemical markers across the decoction process. We established raw material specifications, critical extraction parameters, and stability testing protocols.
Result: Seamless qualification for modern hospital prescription supply with complete batch-to-batch reproducibility.
A transparent, stage-gated development cycle engineered to deliver bulletproof analytical dossiers and reproducible laboratory-to-factory transfers.
Client provides botanical targets, formula ratios, or crude material samples. We determine UV-Vis spectra, ionization modes, solubility, and matrix interference risks.
Column screening (particle morphology, bonded phase), mobile phase gradient fine-tuning, flow rate, column temperature, and detection optimization (UV, DAD, MS, CAD).
Rigorous experimental validation assessing Specificity/Selectivity, Linearity, Accuracy (Spike-recovery 95-105%), Repeatability, Intermediate Precision, LOD/LOQ, and Solution Stability.
Isolation and full spectroscopic characterization (1H-NMR, 13C-NMR, HRMS, HPLC-purity > 98.0%) of certified primary or secondary chemical reference markers.
Bilingual analytical method transfer (AMT) package, including step-by-step instrument parameters, system suitability tests (SST criteria), and remote live video QC guidance.
Compilation of analytical data packages directly formatted for Thai FDA registration, ACTD (ASEAN Common Technical Dossier), or ICH CTD Module 3 submissions.
Clear, uncompromising answers addressing regulatory compliance, intellectual property protection, sample customs transit, and laboratory equipment parity.
We design methods with system ruggedness at the core. When initiating an analytical development protocol for a Bangkok or EEC production facility, we audit the client's laboratory instrument inventory (e.g., Agilent 1260, Waters Arc, Shimadzu Prominence) and select stationary phases (such as Waters Symmetry, Phenomenex Luna, or Agilent ZORBAX) that are readily stocked by local chemical distributors in Thailand. Our transfer protocols define explicit system suitability test (SST) parameters (theoretical plates N > 5000, peak symmetry factor 0.95–1.15, tailing factor T ≤ 1.5, and RSD of peak area < 1.5% across 6 injections) ensuring effortless replication regardless of operator.
Yes. The Thai FDA adheres strictly to the ASEAN Common Technical Dossier (ACTD) format and ICH Q2 guidelines for analytical validation. Our validation reports include full chromatograms with raw baseline integrations, precision data tables (intra-day and intermediate inter-day precision across 3 days by 2 analysts), linearity calibration curves with residual standard deviation analysis, recovery data spanning 80%, 100%, and 120% concentration levels, and forced degradation stress testing (acid, base, peroxide, heat, photolysis). This level of evidence satisfies TFDA reviewers on initial submission.
All contract research is conducted strictly under binding bilateral non-disclosure agreements (NDAs) subject to international trade law. We operate on a pure "entrusted research" model. All chromatography methods, spectral libraries, purified reference standards, and process conditions developed for your specific project remain 100% your exclusive intellectual property. We implement strict digital isolation: project data resides on secure servers with encrypted role-based access, and client analytical projects are blinded with internal alphanumeric codes inside our testing suites.
Our regulatory logistics department maintains verified customs import approvals for plant specimens and botanical active ingredients intended for scientific laboratory analysis. We supply our Bangkok partners with complete guidance documents, including formal invitation letters, customs declarations, and material safety data sheet (MSDS) templates. Standard express air transit (via DHL/FedEx) typically clears into our Changsha testing facility within 4 to 6 business days.
Precisely. Unlike academic testing institutes that only deliver laboratory-scale reports, MedGence / Yineng Biopharm integrates direct contract development and manufacturing (CDMO). Once an analytical method and active compound profile are locked, our pilot-plant and industrial extraction lines can produce standardized active concentrated liquids, dry powders, granules, or finished capsules and tablets under strict cGMP protocols, providing a single accountable supply chain partner from assay design to commercial shipment.
Explore our full lifecycle contract capabilities: from screening and assay creation to pre-clinical and clinical validation.
